DRM02 / Eli Lilly - LARVOL DELTA

Phenotype Spectrum of TRPM3-Associated Disorders. (PubMed, Ann Neurol) - "Developmental delay/intellectual disability and epilepsy are dominant phenotypic features in patients with TRPM3 variants. Given that epilepsy can negatively impact development, screening for awake and sleep electroencephalogram abnormalities and other manifestations are essential to offer early intervention. The TRPM3 channel blocker primidone has shown promising effects and should be considered in every child with a TRPM3 gain-of-function variant. ANN NEUROL 2025;97:561-570."

Journal • Retrospective data • CNS Disorders • Developmental Disorders • Epilepsy • Mental Retardation • Musculoskeletal Diseases • TRPM3

Cannabidiol Nano-Encapsulation To Relief Office Syndrom Pain: Low Back Pain (IASP 2024) - "It was found that these 6 compounds were located in the active sitesurrounding with TYR2038, ARG1773, ARG2166, VAL2176, VAL2002, SER2006, PHE2034, ALA2180, LEU2005, TRP2040, HIS1743 and TYR2008 All of 6 compounds conformations were located close to VAL2176 and ARG2166 a Side pocket of COX-2. These compounds were superimposed with NSAID SC-558, an excellent anti-inflammatory compound, for conformation alignment. Allcompounds conformations show good alignment with SC-558 with means they can inhibit the substrate to reach the enzyme Side pocket."

Back Pain • Lumbar Back Pain • Musculoskeletal Pain • Pain

Primidone improves symptoms in TRPM3-linked DEE-SWAS. (PubMed, Epilepsia) - "We report two unrelated children with pharmaco-resistant DEE-SWAS and developmental delay/regression and different heterozygous de novo missense variants in the TRPM3 gene (NM_001366145.2; c.3397T>C/p.Ser1133Pro, c.2004G>A/p.Val1002Met). To our knowledge, this is the first report of a treatment with primidone in TRPM3-associated CSWS. Our results highlight the importance of early genetic diagnosis in patients with epilepsy and the possibility of precision medicine, which should be considered in future individuals with a TRPM3-linked DEE-SWAS."

Journal • CNS Disorders • Developmental Disorders • Epilepsy • TRPM3

A Safety and Efficacy of DRM02 in Subjects With Atopic Dermatitis (clinicaltrials.gov) - P2; N=21; Completed; Sponsor: Dermira, Inc.; Active, not recruiting -> Completed

Trial completion • Biosimilar • Dermatitis • Eczema • Immunology

A Safety and Efficacy Study of DRM02 in Subjects With Rosacea (clinicaltrials.gov) - P2; N=30; Completed; Sponsor: Dermira, Inc.; Active, not recruiting -> Completed

Trial completion • Biosimilar

A Safety and Efficacy Study of DRM02 in Subjects With Plaque Psoriasis (clinicaltrials.gov) - P2; N=23; Completed; Sponsor: Dermira, Inc.; Active, not recruiting -> Completed

Trial completion • Biosimilar • Immunology • Psoriasis

Identification of serum biomarkers for Systemic Lupus Erythematosus using a library of phage displayed random peptides and deep sequencing. (PubMed, Mol Cell Proteomics) - "Among them, two peptides, i.e., SLE2018Val001 and SLE2018Val002 were confirmed between SLE with other autoimmune patients. The procedure we established could be easily adopted for the identification of autoantibodies as biomarkers for many other diseases."

Biomarker • Journal • Immunology • Lupus • Systemic Lupus Erythematosus

DRM02, a novel phosphodiesterase-4 inhibitor with cutaneous anti-inflammatory activity. (PubMed, Tissue Barriers) - "Further, DRM02 also decreased cutaneous clinical changes and expression of Th17 immune pathway cytokines in a mouse model of psoriasis evoked by repeated topical imiquimod application. Thus, the overall pharmacological profiling of the PDE4 inhibitor DRM02 has revealed its potential as a topical therapy for inflammatory skin disorders and restoration of skin homeostasis."

Journal • Dermatology • Dermatopathology • Immunology • Psoriasis • TNFA